Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study-Reference-Cited by-同舟云学术

Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study

Published:2011-05-19 Issue:2 Volume:26 Page:232-238
ISSN:0269-3879
Container-title:Biomedical Chromatography
language:en
Short-container-title:Biomed. Chromatogr.

Author:

Sharma Sandeep¹,Dubey Naveen Kumar¹,Dasgupta Ashish K.¹,Sahu Monashis²,Benjamin Biju²,Mullangi Ramesh³,Srinivas Nuggehally R.²

Affiliation:

1. Clinsys Clinical Research Limited; C-46, Sector-62; Noida-; 201 307; India

2. Vanthys Pharmaceutical Development (Pvt) Ltd; Phoenix Pinnacle; Ulsoor Road; Bangalore-560 001; India

3. Drug Metabolism and Pharmacokinetics; Jubilant Biosys Ltd, Industrial Suburb; Yeshwanthpur; Bangalore-; 560 022; India

Publisher

Wiley

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry

Reference5 articles.

1. Gurav SD Gilibili RR Jeniffer S Zainuddin M Giri S Govindarajan R Velleca M Srinivas NR Mullangi R Oral bioavailability, permeability, CYP profiling, identification of major metabolites, tissue distribution and excretion profile of a novel triple kinase inhibitor, JI-101 in rats 102nd AACR Annual Meeting 2011

2. Sharma S Miller L Gordon M Srinivas N Sahu M Govindarajan R Mullangi R Northrup J Velleca M Brittelli D Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFR β 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2010a

3. Sharma S Mullangi R Mark W Srinivas N Gurav SD Sajja S Shankar D Govindarajan R Miller L Velleca M PK/PD model using a selective Ephrin B4 inhibitor JI-101 in combination with other targeted agents and chemotherapy: results of preclinical studies 22nd EORTC-NCI-AACR symposium on Molecular targets and Cancer Therapeutics 2010b

4. US DHHS FDA CDER Guidance for Industry: Bioanalytical Method Validation 2001 http://www/fda.gov/cder/guidance/index.htm

5. Velleca M Brittelli D Elkin L Klein U Mitchell S Qian D Qian X Srinivasa S Stephan T Govindarajan R Stern W Gordon M Sharma S Miller L Preclinical and preliminary phase 1 trial results of JI-101: a novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR β AACR-NCI-EORTC International Conference - Molecular Targets and Cancer Therapeutics 2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs;Pharmaceutics;2018-11-08

2. Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors - review of assay methodologies and perspectives;Biomedical Chromatography;2014-11-26